Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Position Statement

Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues

Author(s): Renato Cozzi*, Maria R. Ambrosio, Roberto Attanasio, Alessandro Bozzao, Laura De Marinis, Ernesto De Menis, Edoardo Guastamacchia, Andrea Lania, Giovanni Lasio, Francesco Logoluso, Pietro Maffei, Maurizio Poggi, Vincenzo Toscano, Michele Zini, Philippe Chanson and Laurence Katznelson

Volume 20, Issue 8, 2020

Page: [1144 - 1155] Pages: 12

DOI: 10.2174/1871530320666200129113328

open access plus

Abstract

Any newly diagnosed patient should be referred to a multidisciplinary team experienced in the treatment of pituitary adenomas. The therapeutic management of acromegaly always requires a personalized strategy. Normal age-matched IGF-I values are the treatment goal. Transsphenoidal surgery by an expert neurosurgeon is the primary treatment modality for most patients, especially if there are neurological complications. In patients with poor clinical conditions or who refuse surgery, primary medical treatment should be offered, firstly with somatostatin analogs (SSAs). In patients who do not reach hormonal targets with first-generation depot SSAs, a second pharmacological option with pasireotide LAR or pegvisomant (alone or combined with SSA) should be offered. Irradiation could be proposed to patients with surgical remnants who would like to be free from long-term medical therapies or those with persistent disease activity or tumor growth despite surgery or medical therapy. Since the therapeutic tools available enable therapeutic targets to be achieved in most cases, the challenge is to focus more on the quality of life.

Keywords: Acromegaly, pituitary, neurosurgery, somatostatin analogs, cabergoline, pegvisomant, pasireotide, comorbidities, discrepant, resistant, aggressive, gammaknife.

« Previous Next »
Graphical Abstract

[1]
Casanueva, F.F.; Barkan, A.L.; Buchfelder, M.; Klibanski, A.; Laws, E.R.; Loeffler, J.S.; Melmed, S.; Mortini, P.; Wass, J.; Giustina, A. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A pituitary society statement. Pituitary, 2017, 20(5), 489-498. [no LoE]
[http://dx.doi.org/10.1007/s11102-017-0838-2] [PMID: 28884415]
[2]
Katznelson, L.; Laws, E.R., Jr; Melmed, S.; Molitch, M.E.; Murad, M.H.; Utz, A.; Wass, J.A. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab., 2014, 99(11), 3933-3951. [no LoE]
[http://dx.doi.org/10.1210/jc.2014-2700] [PMID: 25356808]
[3]
Li, A.; Liu, W.; Cao, P.; Zheng, Y.; Bu, Z.; Zhou, T. Endoscopic versus microscopic transsphenoidal surgery in the treatment of pituitary adenoma: A systematic review and meta-analysis. World Neurosurg., 2017, 101(5), 236-246. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1016/j.wneu.2017.01.022] [PMID: 28104521]
[4]
Nomikos, P.; Buchfelder, M.; Fahlbusch, R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur. J. Endocrinol., 2005, 152(3), 379-387. [LoE ⊗⊗ΟΟ
[http://dx.doi.org/10.1530/eje.1.01863] [PMID: 15757854]
[5]
Lissett, C.; Peacey, S.; Laing, I.; Tetlow, L.; Davis, J.R.; Shalet, S.M. The outcome of surgery for acromegaly: The need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin. Endocrinol. (Oxf.), 1998, 49(5), 653-657. [LoE ⊗⊗ΟΟ
[http://dx.doi.org/10.1046/j.1365-2265.1998.00581.x]
[6]
Ahmed, S.; Elsheikh, M.; Stratton, I.M.; Page, R.C.; Adams, C.B.; Wass, J.A. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin. Endocrinol. (Oxf.), 1999, 50(5), 561-567. [LoE ⊗⊗ΟΟ
[http://dx.doi.org/10.1046/j.1365-2265.1999.00760.x]
[7]
Wang, Y.Y.; Higham, C.; Kearney, T.; Davis, J.R.E.; Trainer, P.; Gnanalingham, K.K. Acromegaly surgery in Manchester revisited--the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clin. Endocrinol. (Oxford.), 2012, 76(3), 399-406. [LoE ⊗⊗ΟΟ
[http://dx.doi.org/10.1111/j.1365-2265.2011.04193.x] [PMID: 21824170]
[8]
Anik, I.; Cabuk, B.; Gokbel, A.; Selek, A.; Cetinarslan, B.; Anik, Y.; Ceylan, S. Endoscopic transsphenoidal approach for acromegaly with remission rates in 401 patients: 2010 consensus criteria. World Neurosurg., 2017, 108(12), 278-290. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1016/j.wneu.2017.08.182] [PMID: 28887283]
[9]
Jane, J.A., Jr; Starke, R.M.; Elzoghby, M.A.; Reames, D.L.; Payne, S.C.; Thorner, M.O.; Marshall, J.C.; Laws, E.R., Jr; Vance, M.L. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J. Clin. Endocrinol. Metab., 2011, 96(9), 2732-2740. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2011-0554] [PMID: 21715544]
[10]
Honegger, J.; Grimm, F. The experience with transsphenoidal surgery and its importance to outcomes. Pituitary, 2018, 21(5), 545-555. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-018-0904-4] [PMID: 30062664]
[11]
Briceno, V.; Zaidi, H.A.; Doucette, J.A.; Onomichi, K.B.; Alreshidi, A.; Mekary, R.A.; Smith, T.R. Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis. Neurol. Res., 2017, 39(5), 387-398. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1080/01616412.2017.1296653] [PMID: 28301972]
[12]
Bates, P.R.; Carson, M.N.; Trainer, P.J.; Wass, J.A. Wide variation in surgical outcomes for acromegaly in the UK. Clin. Endocrinol. (Oxf.), 2008, 68(1), 136-142. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1111/j.1365-2265.2007.03012.x] [PMID: 17803712]
[13]
Fleseriu, M.; Hoffman, A.R.; Katznelson, L.; Neuroendocrine, A.A.C.E. American Association of Clinical Endocrinologists and American College of Endocrinology disease state clinical review: management of acromegaly patients: What is the role of pre operative medical therapy? Endocr. Pract., 2015, 21(6), 668-673. [no LoE]
[http://dx.doi.org/10.4158/EP14575.DSCR] [PMID: 26135961]
[14]
Giustina, A.; Chanson, P.; Kleinberg, D.; Bronstein, M.D.; Clemmons, D.R.; Klibanski, A.; van der Lely, A.J.; Strasburger, C.J.; Lamberts, S.W.; Ho, K.K.; Casanueva, F.F.; Melmed, S. Expert consensus document: A consensus on the medical treatment of acromegaly. Nat. Rev. Endocrinol., 2014, 10(4), 243-248. [no LoE]
[http://dx.doi.org/10.1038/nrendo.2014.21] [PMID: 24566817]
[15]
Carlsen, S.M.; Lund-Johansen, M.; Schreiner, T.; Aanderud, S.; Johannesen, O.; Svartberg, J.; Cooper, J.G.; Hald, J.K.; Fougner, S.L.; Bollerslev, J. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial. J. Clin. Endocrinol. Metab., 2008, 93(8), 2984-2990. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2008-0315] [PMID: 18492760]
[16]
Mao, Z.G.; Zhu, Y.H.; Tang, H.L.; Wang, D.Y.; Zhou, J.; He, D.S.; Lan, H.; Luo, B.N.; Wang, H.J. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur. J. Endocrinol., 2010, 162(4), 661-666. [LoE ςςςς
[http://dx.doi.org/10.1530/EJE-09-0908] [PMID: 20061334]
[17]
Li, Z.Q.; Quan, Z.; Tian, H.L.; Cheng, M. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. J. Int. Med. Res., 2012, 40(2), 517-524. [LoE ςςςς
[http://dx.doi.org/10.1177/147323001204000213] [PMID: 22613412]
[18]
Biermasz, N.R.; van Dulken, H.; Roelfsema, F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J. Clin. Endocrinol. Metab., 1999, 84(10), 3551-3555. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jcem.84.10.6027] [PMID: 10522994]
[19]
Losa, M.; Mortini, P.; Urbaz, L.; Ribotto, P.; Castrignanó, T.; Giovanelli, M. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J. Neurosurg., 2006, 104(6), 899-906. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.3171/jns.2006.104.6.899] [PMID: 16776333]
[20]
Nunes, V.S.; Correa, J.M.S.; Puga, M.E.S.; Silva, E.M.K.; Boguszewski, C.L. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: A systematic review and meta-analysis using the GRADE system. Pituitary, 2015, 18(4), 500-508. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-014-0602-9] [PMID: 25261979]
[21]
Losa, M.; Donofrio, C.A.; Gemma, M.; Barzaghi, L.R.; Mortini, P. Pretreatment with somatostatin analogs does not affect the anesthesiologic management of patients with acromegaly. Pituitary, 2019, 22(2), 187-194. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-019-00952-0]
[22]
Colao, A.; Attanasio, R.; Pivonello, R.; Cappabianca, P.; Cavallo, L.M.; Lasio, G.; Lodrini, A.; Lombardi, G.; Cozzi, R. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab., 2006, 91(1), 85-92. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2005-1208] [PMID: 16263832]
[23]
Schwyzer, L.; Starke, R.M.; Jane, J.A., Jr; Oldfield, E.H. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly. J. Neurosurg., 2015, 122(4), 798-802. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.3171/2014.10.JNS14496] [PMID: 25423276]
[24]
Chen, C.J.; Ironside, N.; Pomeraniec, I.J.; Chivukula, S.; Buell, T.J.; Ding, D.; Taylor, D.G.; Dallapiazza, R.F.; Lee, C.C.; Bergsneider, M. Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. Acta Neurochir. (Wien), 2017, 159(11), 2193-2207. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s00701-017-3318-6] [PMID: 28913667]
[25]
Hazer, D.B.; Işık, S.; Berker, D.; Güler, S.; Gürlek, A.; Yücel, T.; Berker, M. Treatment of acromegaly by endoscopic transsphenoidal surgery: Surgical experience in 214 cases and cure rates according to current consensus criteria. J. Neurosurg., 2013, 119(6), 1467-1477. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.3171/2013.8.JNS13224] [PMID: 24074496]
[26]
Negm, H.M.; Al-Mahfoudh, R.; Pai, M.; Singh, H.; Cohen, S.; Dhandapani, S.; Anand, V.K.; Schwartz, T.H. Reoperative endoscopic endonasal surgery for residual or recurrent pituitary adenomas. J. Neurosurg., 2017, 127(2), 397-408. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.3171/2016.8.JNS152709] [PMID: 27791524]
[27]
Esquenazi, Y.; Essayed, W.I.; Singh, H.; Mauer, E.; Ahmed, M.; Christos, P.J.; Schwartz, T.H. Endoscopic endonasal versus microscopic transsphenoidal surgery for recurrent and/or residual pituitary adenomas. World Neurosurg., 2017, 101(5), 186-195. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1016/j.wneu.2017.01.110] [PMID: 28185971]
[28]
Gadelha, M.R.; Wildemberg, L.E.; Bronstein, M.D.; Gatto, F.; Ferone, D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary, 2017, 20(1), 1080-108. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-017-0791-0] [PMID: 28176162]
[29]
Freda, P.U.; Katznelson, L.; van der Lely, A.J.; Reyes, C.M.; Zhao, S.; Rabinowitz, D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab., 2005, 90(8), 4465-4473. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2005-0260] [PMID: 15886238]
[30]
Murray, R.D.; Melmed, S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J. Clin. Endocrinol. Metab., 2008, 93(8), 2957-2968. [no LoE]
[http://dx.doi.org/10.1210/jc.2008-0027] [PMID: 18477663]
[31]
Maiza, J.C.; Vezzosi, D.; Matta, M.; Donadille, F.; Loubes-Lacroix, F.; Cournot, M.; Bennet, A.; Caron, P. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH secreting pituitary adenoma responsive to SSTa. Clin. Endocrinol. (Oxf.), 2007, 67(2), 282-289. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1111/j.1365-2265.2007.02878.x] [PMID: 17524029]
[32]
Andries, M.; Glintborg, D.; Kvistborg, A.; Hagen, C.; Andersen, M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin. Endocrinol. (Oxf.), 2008, 68(3), 473-480. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1111/j.1365-2265.2007.03067.x] [PMID: 17941902]
[33]
Tutuncu, Y.; Berker, D.; Isik, S.; Ozuguz, U.; Akbaba, G.; Kucukler, F.K.; Aydin, Y.; Guler, S. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary, 2012, 15(3), 398-404. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-011-0335-y] [PMID: 21863263]
[34]
Alquraini, H.; Del Pilar Schneider, M.; Mirakhur, B.; Barkan, A. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: Analysis of three multicenter clinical trials. Pituitary, 2018, 21(3), 283-289. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-018-0867-5] [PMID: 29357081]
[35]
Lancranjan, I.; Atkinson, B.A. Results of a European multicentre study with Sandostatin LAR in acromegaly patients. Pituitary, 1999, 1(2), 105-114. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1023/A:1009980404404]
[36]
Caron, P.J.; Bevan, J.S.; Petersenn, S.; Houchard, A.; Sert, C.; Webb, S.M. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: Data from the PRIMARYS study. Pituitary, 2016, 19(2), 149-157. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-015-0693-y] [PMID: 26603536]
[37]
Colao, A.; Ferone, D.; Marzullo, P.; Lombardi, G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr. Rev., 2004, 25(1), 102-152. [no LoE]
[http://dx.doi.org/10.1210/er.2002-0022] [PMID: 14769829]
[38]
Maison, P.; Tropeano, A.I.; Macquin-Mavier, I.; Giustina, A.; Chanson, P. Impact of somatostatin analogs on the heart in acromegaly: A metaanalysis. J. Clin. Endocrinol. Metab., 2007, 92(5), 1743-1747. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2006-2547] [PMID: 17311857]
[39]
Melmed, S.; Sternberg, R.; Cook, D.; Klibanski, A.; Chanson, P.; Bonert, V.; Vance, M.L.; Rhew, D.; Kleinberg, D.; Barkan, A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J. Clin. Endocrinol. Metab., 2005, 90(7), 4405-4410. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2004-2466] [PMID: 15827109]
[40]
Bevan, J.S. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab., 2005, 90(3), 1856-1863. [no LoE
[http://dx.doi.org/10.1210/jc.2004-1093] [PMID: 15613435]
[41]
Cozzi, R.; Montini, M.; Attanasio, R.; Albizzi, M.; Lasio, G.; Lodrini, S.; Doneda, P.; Cortesi, L.; Pagani, G. Primary treatment of acromegaly with octreotide LAR: A long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J. Clin. Endocrinol. Metab., 2006, 91(4), 1397-1403. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2005-2347] [PMID: 16449332]
[42]
Caron, P.J.; Bevan, J.S.; Petersenn, S.; Flanagan, D.; Tabarin, A.; Prévost, G.; Maisonobe, P.; Clermont, A. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: Results of a prospective multicenter clinical trial. J. Clin. Endocrinol. Metab., 2014, 99(4), 1282-1290. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2013-3318] [PMID: 24423301]
[43]
Colao, A.; Auriemma, R.S.; Pivonello, R. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary, 2016, 19(2), 210-221. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-015-0677-y] [PMID: 26290466]
[44]
Cozzi, R.; Attanasio, R.; Montini, M.; Pagani, G.; Lasio, G.; Lodrini, S.; Barausse, M.; Albizzi, M.; Dallabonzana, D.; Pedroncelli, A.M. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J. Clin. Endocrinol. Metab., 2003, 88(7), 3090-3098. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2003-030110] [PMID: 12843148]
[45]
Colao, A.; Pivonello, R.; Cappabianca, P.; Briganti, F.; Tortora, F.; Auriemma, R.S.; De Martino, M.C.; Marzullo, P.; Lombardi, G. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin. Endocrinol. (Oxf.), 2005, 63(3), 342-349. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1111/j.1365-2265.2005.02351.x] [PMID: 16117824]
[46]
Potorac, I.; Petrossians, P.; Daly, A.F.; Alexopoulou, O.; Borot, S.; Sahnoun-Fathallah, M.; Castinetti, F.; Devuyst, F.; Jaffrain-Rea, M.L.; Briet, C.; Luca, F.; Lapoirie, M.; Zoicas, F.; Simoneau, I.; Diallo, A.M.; Muhammad, A.; Kelestimur, F.; Nazzari, E.; Centeno, R.G.; Webb, S.M.; Nunes, M.L.; Hana, V.; Pascal-Vigneron, V.; Ilovayskaya, I.; Nasybullina, F.; Achir, S.; Ferone, D.; Neggers, S.J.C.M.M.; Delemer, B.; Petit, J.M.; Schöfl, C.; Raverot, G.; Goichot, B.; Rodien, P.; Corvilain, B.; Brue, T.; Schillo, F.; Tshibanda, L.; Maiter, D.; Bonneville, J.F.; Beckers, A. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr. Relat. Cancer, 2016, 23(11), 871-881. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/ERC-16-0356] [PMID: 27649724]
[47]
Shen, M.; Zhang, Q.; Liu, W.; Wang, M.; Zhu, J.; Ma, Z.; He, W.; Li, S.; Shou, X.; Li, Y.; Zhang, Z.; Ye, H.; He, M.; Lu, B.; Yao, Z.; Lu, Y.; Qiao, N.; Ye, Z.; Zhang, Y.; Yang, Y.; Zhao, Y.; Wang, Y. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology, 2016, 58(11), 1057-1065. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s00234-016-1728-4] [PMID: 27516099]
[48]
Potorac, I.; Beckers, A.; Bonneville, J.F. T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: A perspective. Pituitary, 2017, 20(1), 116-120. [no LoE
[http://dx.doi.org/10.1007/s11102-017-0788-8] [PMID: 28197813]
[49]
Heck, A.; Ringstad, G.; Fougner, S.L.; Casar-Borota, O.; Nome, T.; Ramm-Pettersen, J.; Bollerslev, J. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin. Endocrinol. (Oxf.), 2012, 77(1), 72-78. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1111/j.1365-2265.2011.04286.x] [PMID: 22066905]
[50]
Fougner, S.L.; Casar-Borota, O.; Heck, A.; Berg, J.P.; Bollerslev, J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. (Oxf.), 2012, 76(1), 96-102. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1111/j.1365-2265.2011.04163.x] [PMID: 21722151]
[51]
Taboada, G.F.; Luque, R.M.; Neto, L.V. Machado, Ede.O.; Sbaffi, B.C.; Domingues, R.C.; Marcondes, J.B.; Chimelli, L.M.; Fontes, R.; Niemeyer, P.; de Carvalho, D.P.; Kineman, R.D.; Gadelha, M.R. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur. J. Endocrinol., 2008, 158(3), 295-303. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EJE-07-0562] [PMID: 18299461]
[52]
Casarini, A.P.; Jallad, R.S.; Pinto, E.M.; Soares, I.C.; Nonogaki, S.; Giannella-Neto, D.; Musolino, N.R.; Alves, V.A.; Bronstein, M.D. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary, 2009, 12(4), 297-303. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-009-0175-1] [PMID: 19330452]
[53]
Neggers, S.J.; Pronin, V.; Balcere, I.; Lee, M.K.; Rozhinskaya, L.; Bronstein, M.D.; Gadelha, M.R.; Maisonobe, P.; Sert, C.; van der Lely, A.J. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur. J. Endocrinol., 2015, 173(3), 313-323. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EJE-15-0215] [PMID: 26047625]
[54]
Giustina, A.; Bonadonna, S.; Bugari, G.; Colao, A.; Cozzi, R.; Cannavò, S.; de Marinis, L.; Degli Uberti, E.; Bogazzi, F.; Mazziotti, G.; Minuto, F.; Montini, M.; Ghigo, E. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol., 2009, 161(2), 331-338. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EJE-09-0372] [PMID: 19465485]
[55]
Giustina, A.; Mazziotti, G.; Cannavò, S.; Castello, R.; Arnaldi, G.; Bugari, G.; Cozzi, R.; Ferone, D.; Formenti, A.M.; Gatti, E.; Grottoli, S.; Maffei, P.; Maffezzoni, F.; Montini, M.; Terzolo, M.; Ghigo, E. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J. Clin. Endocrinol. Metab., 2017, 102(7), 2454-2464. [LoE ςςςς
[http://dx.doi.org/10.1210/jc.2017-00142] [PMID: 28419317]
[56]
Casagrande, A.; Bronstein, M.D.; Jallad, R.S.; Moraes, A.B.; Elias, P.C.L.; Castro, M.; Czepielewski, M.A.; Boschi, A.; Ribeiro-Oliveira, A., Jr; Schweizer, J.R.; Vilar, L.; Nazato, D.M.; Gadelha, M.R.; Abucham, J. Schweizer JROL, Vilar L, Nazato DM, Gadelha MR, Abucham J. Long-term remission of acromegaly after octreotide withdrawal is an uncommon and frequently unsustainable event. Neuroendocrinology, 2017, 104(3), 273-279. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1159/000446542] [PMID: 27161443]
[57]
Mazziotti, G.; Floriani, I.; Bonadonna, S.; Torri, V.; Chanson, P.; Giustina, A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab., 2009, 94(5), 1500-1508. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2008-2332] [PMID: 19208728]
[58]
Mazziotti, G.; Porcelli, T.; Bogazzi, F.; Bugari, G.; Cannavò, S.; Colao, A.; Cozzi, R.; De Marinis, L. degli Uberti, E.; Grottoli, S.; Minuto, F.; Montini, M.; Spinello, M.; Giustina, A. Effects of high dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur. J. Endocrinol., 2011, 164(3), 341-347. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EJE-10-0811] [PMID: 21212103]
[59]
Cozzolino, A.; Feola, T.; Simonelli, I.; Puliani, G.; Pozza, C.; Giannetta, E.; Gianfrilli, D.; Pasqualetti, P.; Lenzi, A.; Isidori, A.M. Somatostatin analogs and glucose metabolism in acromegaly: A meta-analysis of prospective interventional studies. J. Clin. Endocrinol. Metab., 2018, 103(6), 2089-2099. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2017-02566] [PMID: 29590371]
[60]
Baroni, M.G.; Giorgino, F.; Pezzino, V.; Scaroni, C.; Avogaro, A. Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly. J. Endocrinol. Invest., 2016, 39(2), 235-255. [no LoE
[http://dx.doi.org/10.1007/s40618-015-0404-6] [PMID: 26718207]
[61]
Bruns, C.; Lewis, I.; Briner, U.; Meno-Tetang, G.; Weckbecker, G. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol., 2002, 146(5), 707-716. [no LoE] 2002.
[http://dx.doi.org/10.1530/eje.0.1460707] [PMID: 11980628]
[62]
Petersenn, S.; Schopohl, J.; Barkan, A.; Mohideen, P.; Colao, A.; Abs, R.; Buchelt, A.; Ho, Y.Y.; Hu, K.; Farrall, A.J.; Melmed, S.; Biller, B.M. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: A randomized, multicenter, phase II trial. J. Clin. Endocrinol. Metab., 2010, 95(6), 2781-2789. [LoE ςςςς
[http://dx.doi.org/10.1210/jc.2009-2272] [PMID: 20410233]
[63]
Petersenn, S.; Bollerslev, J.; Arafat, A.M.; Schopohl, J.; Serri, O.; Katznelson, L.; Lasher, J.; Hughes, G.; Hu, K.; Shen, G.; Reséndiz, K.H.; Giannone, V.; Beckers, A. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. J. Clin. Pharmacol., 2014, 54(11), 1308-1317. [LoE ςςςς
[http://dx.doi.org/10.1002/jcph.326] [PMID: 24800725]
[64]
Petersenn, S.; Farrall, A.J.; De Block, C.; Melmed, S.; Schopohl, J.; Caron, P.; Cuneo, R.; Kleinberg, D.; Colao, A.; Ruffin, M.; Hermosillo Reséndiz, K.; Hughes, G.; Hu, K.; Barkan, A. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: Results from an open-ended, multicenter, Phase II extension study. Pituitary, 2014, 17(2), 132-140. [LoE ςςςς
[http://dx.doi.org/10.1007/s11102-013-0478-0] [PMID: 23529827]
[65]
Colao, A.; Bronstein, M.D.; Freda, P.; Gu, F.; Shen, C.C.; Gadelha, M.; Fleseriu, M.; van der Lely, A.J.; Farrall, A.J.; Hermosillo Reséndiz, K.; Ruffin, M.; Chen, Y.; Sheppard, M. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab., 2014, 99(3), 791-799. [LoE ςςςς
[http://dx.doi.org/10.1210/jc.2013-2480] [PMID: 24423324]
[66]
Gadelha, M.R.; Bronstein, M.D.; Brue, T.; Coculescu, M.; Fleseriu, M.; Guitelman, M.; Pronin, V.; Raverot, G.; Shimon, I.; Lievre, K.K.; Fleck, J.; Aout, M.; Pedroncelli, A.M.; Colao, A. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial. Lancet Diabetes Endocrinol., 2014, 2(11), 875-884. [LoE ςςςς
[http://dx.doi.org/10.1016/S2213-8587(14)70169-X] [PMID: 25260838]
[67]
Sheppard, M.; Bronstein, M.D.; Freda, P.; Serri, O.; De Marinis, L.; Naves, L.; Rozhinskaya, L.; Hermosillo Reséndiz, K.; Ruffin, M.; Chen, Y.; Colao, A. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: Results from the blinded extension phase of a randomized, double blind, multicenter, Phase III study. Pituitary, 2015, 18(3), 385-394. [LoE ςςςς
[http://dx.doi.org/10.1007/s11102-014-0585-6] [PMID: 25103549]
[68]
Bronstein, M.D.; Fleseriu, M.; Neggers, S.; Colao, A.; Sheppard, M.; Gu, F.; Shen, C.C.; Gadelha, M.; Farrall, A.J.; Hermosillo Reséndiz, K.; Ruffin, M.; Chen, Y.; Freda, P. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: Crossover extension to a randomized, double blind, Phase III study. BMC Endocr. Disord., 2016, 16, 16. [LoE ςςςς
[http://dx.doi.org/10.1186/s12902-016-0096-8] [PMID: 27039081]
[69]
Shimon, I.; Adnan, Z.; Gorshtein, A.; Baraf, L.; Saba Khazen, N.; Gershinsky, M.; Pauker, Y.; Abid, A.; Niven, M.J.; Shechner, C.; Greenman, Y. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: A multicenter study. Endocrine, 2018, 62(2), 448-455. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s12020-018-1690-5] [PMID: 30051198]
[70]
Marina, D.; Burman, P.; Klose, M.; Casar-Borota, O.; Luque, R.M.; Castaño, J.P.; Feldt-Rasmussen, U. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache. Growth Horm. IGF Res., 2015, 25(5), 262-267. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1016/j.ghir.2015.07.003] [PMID: 26188991]
[71]
Amarawardena, W.K.M.G.; Liyanarachchi, K.D.; Newell-Price, J.D.C.; Ross, R.J.M.; Iacovazzo, D.; Debono, M. Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly. Endocrinol. Diabetes Metab. Case Rep., 2017, 2017(1), 17-0067. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EDM-17-0067] [PMID: 28721221]
[72]
Coopmans, E.C.; Muhammad, A.; van der Lely, A.J.; Janssen, J.A.M.J.L.; Neggers, S.J.C.M.M. How to position pasireotide LAR treatment in acromegaly. J. Clin. Endocrinol. Metab., 2019, 104(6), 1978-1988. [no LoE
[http://dx.doi.org/10.1210/jc.2018-01979] [PMID: 30608534]
[73]
Iacovazzo, D.; Carlsen, E.; Lugli, F.; Chiloiro, S.; Piacentini, S.; Bianchi, A.; Giampietro, A.; Mormando, M.; Clear, A.J.; Doglietto, F.; Anile, C.; Maira, G.; Lauriola, L.; Rindi, G.; Roncaroli, F.; Pontecorvi, A.; Korbonits, M.; De Marinis, L. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study. Eur. J. Endocrinol., 2016, 174(2), 241-250. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EJE-15-0832] [PMID: 26586796]
[74]
Schmid, H.A.; Brue, T.; Colao, A.; Gadelha, M.R.; Shimon, I.; Kapur, K.; Pedroncelli, A.M.; Fleseriu, M. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine, 2016, 53(1), 210-219. [LoE ςςςς
[http://dx.doi.org/10.1007/s12020-016-0895-8] [PMID: 26906713]
[75]
Colao, A.; De Block, C.; Gaztambide, M.S.; Kumar, S.; Seufert, J.; Casanueva, F.F. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: Medical expert recommendations. Pituitary, 2014, 17(2), 180-186. [no LoE
[http://dx.doi.org/10.1007/s11102-013-0483-3] [PMID: 23564338]
[76]
Samson, S.L. Management of hyperglycemia in patients with acromegaly treated with pasireotide LAR. Drugs, 2016, 76(13), 1235-1243. [no LoE
[http://dx.doi.org/10.1007/s40265-016-0615-y] [PMID: 27473537]
[77]
Fleseriu, M.; Rusch, E.; Geer, E.B. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine, 2017, 55(1), 247-255. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s12020-016-1182-4] [PMID: 27896545]
[78]
Kopchick, J.J.; Parkinson, C.; Stevens, E.C.; Trainer, P.J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev., 2002, 23(5), 623-646. [no LoE
[http://dx.doi.org/10.1210/er.2001-0022] [PMID: 12372843]
[79]
Trainer, P.J.; Drake, W.M.; Katznelson, L.; Freda, P.U.; Herman-Bonert, V.; van der Lely, A.J.; Dimaraki, E.V.; Stewart, P.M.; Friend, K.E.; Vance, M.L.; Besser, G.M.; Scarlett, J.A.; Thorner, M.O.; Parkinson, C.; Klibanski, A.; Powell, J.S.; Barkan, A.L.; Sheppard, M.C.; Malsonado, M.; Rose, D.R.; Clemmons, D.R.; Johannsson, G.; Bengtsson, B.A.; Stavrou, S.; Kleinberg, D.L.; Cook, D.M.; Phillips, L.S.; Bidlingmaier, M.; Strasburger, C.J.; Hackett, S.; Zib, K.; Bennett, W.F.; Davis, R.J. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med., 2000, 342(16), 1171-1177. [LoE ςςςς
[http://dx.doi.org/10.1056/NEJM200004203421604] [PMID: 10770982]
[80]
van der Lely, A.J.; Hutson, T.K.; Trainer, P.J.; Besser, G.M.; Barkan, A.L.; Katznelson, L.; Klibanski, A.; Herman-Bonert, V.; Melmed, S.; Vance, M.L.; Freda, P.U.; Stewart, P.; Friend, K.E.; Clemmons, D.R.; Johannsson, G.; Stavrou, S.; Cook, D.M.; Phillips, L.S.; Strasburger, C.J.; Hackett, S.; Zib, K.; Davis, R.J.; Scarlett, J.A.; Thorner, M.O. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 2001, 358(9295), 1754-1759. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1016/S0140-6736(01)06844-1]
[81]
Buchfelder, M.; van der Lely, A.J.; Biller, B.M.K.; Webb, S.M.; Brue, T.; Strasburger, C.J.; Ghigo, E.; Camacho-Hubner, C.; Pan, K.; Lavenberg, J.; Jönsson, P.; Hey-Hadavi, J.H. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur. J. Endocrinol., 2018, 179(6), 419-427. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EJE-18-0616] [PMID: 30325178]
[82]
Feola, T.; Cozzolino, A.; Simonelli, I.; Sbardella, E.; Pozza, C.; Giannetta, E.; Gianfrilli, D.; Pasqualetti, P.; Lenzi, A.; Isidori, A.M. Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J. Clin. Endocrinol. Metab., 2019, 104(7), 2892-2902. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2018-02281] [PMID: 30869797]
[83]
Sandret, L.; Maison, P.; Chanson, P. Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab., 2011, 96(5), 1327-1335. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2010-2443] [PMID: 21325455]
[84]
Mattar, P.; Alves Martins, M.R.; Abucham, J. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology, 2010, 92(2), 120-127. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1159/000317314] [PMID: 20802256]
[85]
Vilar, L.; Azevedo, M.F.; Naves, L.A.; Casulari, L.A.; Albuquerque, J.L.; Montenegro, R.M.; Montenegro, R.M., Jr; Figueiredo, P.; Nascimento, G.C.; Faria, M.S. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary, 2011, 14(2), 148-156. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-010-0272-1] [PMID: 21104199]
[86]
Suda, K.; Inoshita, N.; Iguchi, G.; Fukuoka, H.; Takahashi, M.; Nishizawa, H.; Yamamoto, M.; Yamada, S.; Takahashi, Y. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: A retrospective clinical study and review of the literature. Endocr. J., 2013, 60(4), 507-515. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1507/endocrj.EJ12-0272] [PMID: 23291436]
[87]
Feenstra, J.; de Herder, W.W.; ten Have, S.M.; van den Beld, A.W.; Feelders, R.A.; Janssen, J.A.; van der Lely, A.J. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet, 2005, 365(9471), 1644-1646. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1016/S0140-6736(05)63011-5] [PMID: 15885297]
[88]
Neggers, S.J.; van Aken, M.O.; Janssen, J.A.; Feelders, R.A.; de Herder, W.W.; van der Lely, A.J. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab., 2007, 92(12), 4598-4601. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2007-1234] [PMID: 17895318]
[89]
Trainer, P.J.; Ezzat, S.; D’Souza, G.A.; Layton, G.; Strasburger, C.J. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and longacting octreotide in patients with acromegaly. Clin. Endocrinol. (Oxf.), 2009, 71(4), 549-557. [LoE ςςςς
[http://dx.doi.org/10.1111/j.1365-2265.2009.03620.x] [PMID: 19438906]
[90]
van der Lely, A.J.; Bernabeu, I.; Cap, J.; Caron, P.; Colao, A.; Marek, J.; Neggers, S.; Birman, P. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur. J. Endocrinol., 2011, 164(3), 325-333. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EJE-10-0867] [PMID: 21148630]
[91]
Bianchi, A.; Valentini, F.; Iuorio, R.; Poggi, M.; Baldelli, R.; Passeri, M.; Giampietro, A.; Tartaglione, L.; Chiloiro, S.; Appetecchia, M.; Gargiulo, P.; Fabbri, A.; Toscano, V.; Pontecorvi, A.; De Marinis, L. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J. Exp. Clin. Cancer Res., 2013, 32, 40. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1186/1756-9966-32-40] [PMID: 23799893]
[92]
Neggers, S.J.; Franck, S.E.; de Rooij, F.W.; Dallenga, A.H.; Poublon, R.M.; Feelders, R.A.; Janssen, J.A.; Buchfelder, M.; Hofland, L.J.; Jørgensen, J.O.; van der Lely, A.J. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab., 2014, 99(10), 3644-3652. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2014-2032] [PMID: 24937542]
[93]
Muhammad, A.; van der Lely, A.J.; Delhanty, P.J.D.; Dallenga, A.H.G.; Haitsma, I.K.; Janssen, J.A.M.J.L.; Neggers, S.J.C.M.M. Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE Study). J. Clin. Endocrinol. Metab., 2018, 103(2), 586-595. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2017-02017] [PMID: 29155991]
[94]
Chiloiro, S.; Bima, C.; Tartaglione, T.; Giampietro, A.; Gessi, M.; Lauretti, L.; Anile, C.; Colosimo, C.; Rindi, G.; Pontecorvi, A.; De Marinis, L.; Bianchi, A. Pasireotide and pegvisomant combination treatment in acromegaly resistant to second line therapies: A longitudinal study. J. Clin. Endocrinol. Metab., 2019, 104(11), 5478-5482. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2019-00825] [PMID: 31219586]
[95]
Higham, C.E.; Atkinson, A.B.; Aylwin, S.; Bidlingmaier, M.; Drake, W.M.; Lewis, A.; Martin, N.M.; Moyes, V.; Newell-Price, J.; Trainer, P.J. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: A prospective clinical trial. J. Clin. Endocrinol. Metab., 2012, 97(4), 1187-1193. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2011-2603] [PMID: 22278424]
[96]
Bernabeu, I.; Alvarez-Escolá, C.; Paniagua, A.E.; Lucas, T.; Pavón, I.; Cabezas-Agrícola, J.M.; Casanueva, F.F.; Marazuela, M. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary, 2013, 16(1), 101-108. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-012-0382-z] [PMID: 22396133]
[97]
Stone, J.C.; Clark, J.; Cuneo, R.; Russell, A.W.; Doi, S.A. Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: A meta-analysis of published observational studies. Pituitary, 2014, 17(3), 284-295. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-013-0504-2] [PMID: 23925896]
[98]
Kim, E.H.; Oh, M.C.; Chang, J.H.; Moon, J.H.; Ku, C.R.; Chang, W.S.; Lee, E.J.; Kim, S.H. Postoperative gamma knife radiosurgery for cavernous sinus-invading growth hormone-secreting pituitary adenomas. World Neurosurg., 2018, 110(2), e534-e545. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1016/j.wneu.2017.11.043] [PMID: 29155347]
[99]
Zibar Tomšić, K.; Dušek, T.; Kraljević, I.; Heinrich, Z.; Solak, M.; Vučinović, A.; Ozretić, D.; Mihailović Marasanov, S.; Hršak, H.; Kaštelan, D. Hypopituitarism after gamma knife radiosurgery for pituitary adenoma. Endocr. Res., 2017, 42(4), 318-324. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1080/07435800.2017.1323913] [PMID: 28537768]
[100]
Abu Dabrh, A.M.; Asi, N.; Farah, W.H.; Mohammed, K.; Wang, Z.; Farah, M.H.; Prokop, L.J.; Katznelson, L.; Murad, M.H. Radiotherapy versus radiosurgery in treating patients with acromegaly: A systematic review and meta-analysis. Endocr. Pract., 2015, 21(8), 943-945. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.4158/EP14574.OR]
[101]
Milanese, L.; Martini, C.; Scaroni, C.; Dassie, F.; Ceccato, F.; Della Puppa, A.; Denaro, L.; Bommarito, G.; Citton, V.; Ermani, M.; Maffei, P.; Manara, R. Radiotherapy in acromegaly: Long-term brain parenchymal and vascular magnetic resonance changes. J. Neuroradiol., 2018, 45(5), 323-328. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1016/j.neurad.2018.02.004] [PMID: 29505842]
[102]
Fleseriu, M.; Hashim, I.A.; Karavitaki, N.; Melmed, S.; Murad, M.H.; Salvatori, R.; Samuels, M.H. Hormonal replacement in hypopituitarism in adults: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2016, 101(11), 3888-3921. [no LoE
[http://dx.doi.org/10.1210/jc.2016-2118] [PMID: 27736313]
[103]
Di Ieva, A.; Rotondo, F.; Syro, L.V.; Cusimano, M.D.; Kovacs, K. Aggressive pituitary adenomas--diagnosis and emerging treatments. Nat. Rev. Endocrinol., 2014, 10(7), 423-435. [no LoE
[http://dx.doi.org/10.1038/nrendo.2014.64] [PMID: 24821329]
[104]
Chatzellis, E.; Alexandraki, K.I.; Androulakis, I.I.; Kaltsas, G. Aggressive pituitary tumors. Neuroendocrinology, 2015, 101(2), 87-104. [no LoE
[http://dx.doi.org/10.1159/000371806] [PMID: 25571935]
[105]
Raverot, G.; Burman, P.; McCormack, A.; Heaney, A.; Petersenn, S.; Popovic, V.; Trouillas, J.; Dekkers, O.M. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol., 2018, 178(1), G1-G24. [no LoE
[http://dx.doi.org/10.1530/EJE-17-0796]
[106]
Lopes, M.B.S. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol., 2017, 134(4), 521-535. [no LoE
[http://dx.doi.org/10.1007/s00401-017-1769-8] [PMID: 28821944]
[107]
Asa, S.L.; Casar-Borota, O.; Chanson, P.; Delgrange, E.; Earls, P.; Ezzat, S.; Grossman, A.; Ikeda, H.; Inoshita, N.; Karavitaki, N.; Korbonits, M.; Laws, E.R., Jr; Lopes, M.B.; Maartens, N.; McCutcheon, I.E.; Mete, O.; Nishioka, H.; Raverot, G.; Roncaroli, F.; Saeger, W.; Syro, L.V.; Vasiljevic, A.; Villa, C.; Wierinckx, A.; Trouillas, J. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr. Relat. Cancer, 2017, 24(4), C5-C8. [no LoE
[http://dx.doi.org/10.1530/ERC-17-0004] [PMID: 28264912]
[108]
Donoho, D.A.; Bose, N.; Zada, G.; Carmichael, J.D. Management of aggressive growth hormone secreting pituitary adenomas. Pituitary, 2017, 20(1), 169-178. [no LoE
[http://dx.doi.org/10.1007/s11102-016-0781-7] [PMID: 27987061]
[109]
Mete, O.; Ezzat, S.; Asa, S.L. Biomarkers of aggressive pituitary adenomas. J. Mol. Endocrinol., 2012, 49(2), R69-R78. [no LoE
[http://dx.doi.org/10.1530/JME-12-0113] [PMID: 22822048]
[110]
Bengtsson, D.; Schrøder, H.D.; Andersen, M.; Maiter, D.; Berinder, K.; Feldt Rasmussen, U.; Rasmussen, Å.K.; Johannsson, G.; Hoybye, C.; van der Lely, A.J.; Petersson, M.; Ragnarsson, O.; Burman, P. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J. Clin. Endocrinol. Metab., 2015, 100(4), 1689-1698. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2014-4350] [PMID: 25646794]
[111]
Raverot, G.; Sturm, N.; de Fraipont, F.; Muller, M.; Salenave, S.; Caron, P.; Chabre, O.; Chanson, P.; Cortet-Rudelli, C.; Assaker, R.; Dufour, H.; Gaillard, S.; François, P.; Jouanneau, E.; Passagia, J.G.; Bernier, M.; Cornélius, A.; Figarella-Branger, D.; Trouillas, J.; Borson-Chazot, F.; Brue, T. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: A French multicenter experience. J. Clin. Endocrinol. Metab., 2010, 95(10), 4592-4599. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2010-0644] [PMID: 20660056]
[112]
Lasolle, H.; Cortet, C.; Castinetti, F.; Cloix, L.; Caron, P.; Delemer, B.; Desailloud, R.; Jublanc, C.; Lebrun-Frenay, C.; Sadoul, J.L.; Taillandier, L.; Batisse-Lignier, M.; Bonnet, F.; Bourcigaux, N.; Bresson, D.; Chabre, O.; Chanson, P.; Garcia, C.; Haissaguerre, M.; Reznik, Y.; Borot, S.; Villa, C.; Vasiljevic, A.; Gaillard, S.; Jouanneau, E.; Assié, G.; Raverot, G. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur. J. Endocrinol., 2017, 176(6), 769-777. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EJE-16-0979] [PMID: 28432119]
[113]
McCormack, A.; Dekkers, O.M.; Petersenn, S.; Popovic, V.; Trouillas, J.; Raverot, G.; Burman, P. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur. J. Endocrinol., 2018, 178(3), 265-276. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EJE-17-0933]
[114]
Halevy, C.; Whitelaw, B.C. How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary, 2017, 20(2), 261-266. [no LoE
[http://dx.doi.org/10.1007/s11102-016-0745-y] [PMID: 27581836]
[115]
Syro, L.V.; Rotondo, F.; Ortiz, L.D.; Kovacs, K. Treatment of pituitary tumors with temozolomide: an update. Endocr. Relat. Cancer, 2018, 25(8), T159-T169. [no LoE
[http://dx.doi.org/10.1530/ERC-18-0015]
[116]
Maclean, J.; Aldridge, M.; Bomanji, J.; Short, S.; Fersht, N. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: Variable clinical response in preliminary evaluation. Pituitary, 2014, 17(6), 530-538. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-013-0540-y] [PMID: 24323313]
[117]
Waligórska-Stachura, J.; Gut, P.; Sawicka-Gutaj, N.; Liebert, W.; Gryczyńska, M.; Baszko-Błaszyk, D.; Blanco-Gangoo, A.R.; Ruchała, M. Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: Case report. J. Neurosurg., 2016, 125(2), 346-349. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.3171/2015.6.JNS15363] [PMID: 26636388]
[118]
Kong, X.; Gong, S.; Su, L.; Howard, N.; Kong, Y. Automatic detection of acromegaly from facial photographs using machine learning methods. EBioMedicine, 2018, 27(1), 94-102. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1016/j.ebiom.2017.12.015]
[119]
Giustina, A.; Bevan, J.S.; Bronstein, M.D.; Casanueva, F.F.; Chanson, P.; Petersenn, S.; Thanh, X.M.; Sert, C.; Houchard, A.; Guillemin, I.; Melmed, S. SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study. Pituitary, 2016, 19(1), 39-49. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-015-0681-2] [PMID: 26377024]
[120]
van der Lely, A.J.; Gomez, R.; Pleil, A.; Badia, X.; Brue, T.; Buchfelder, M.; Burman, P.; Clemmons, D.; Ghigo, E.; Jørgensen, J.O.L.; Luger, A.; van der Lans-Bussemaker, J.; Webb, S.M.; Strasburger, C.J. Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary, 2017, 20(6), 692-701. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1007/s11102-017-0835-5] [PMID: 28887782]
[121]
Melmed, S.; Popovic, V.; Bidlingmaier, M.; Mercado, M.; van der Lely, A.J.; Biermasz, N.; Bolanowski, M.; Coculescu, M.; Schopohl, J.; Racz, K.; Glaser, B.; Goth, M.; Greenman, Y.; Trainer, P.; Mezosi, E.; Shimon, I.; Giustina, A.; Korbonits, M.; Bronstein, M.D.; Kleinberg, D.; Teichman, S.; Gliko-Kabir, I.; Mamluk, R.; Haviv, A.; Strasburger, C. Safety and efficacy of oral octreotide in acromegaly: Results of a multicenter phase III trial. J. Clin. Endocrinol. Metab., 2015, 100(4), 1699-1708. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2014-4113] [PMID: 25664604]
[122]
Chieffo, C.; Cook, D.; Xiang, Q.; Frohman, L.A. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J. Clin. Endocrinol. Metab., 2013, 98(10), 4047-4054. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1210/jc.2013-2262] [PMID: 23969184]
[123]
Trainer, P.J.; Newell-Price, J.D.C.; Ayuk, J.; Aylwin, S.J.B.; Rees, A.; Drake, W.; Chanson, P.; Brue, T.; Webb, S.M.; Fajardo, C.; Aller, J.; McCormack, A.I.; Torpy, D.J.; Tachas, G.; Atley, L.; Ryder, D.; Bidlingmaier, M. A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. Eur. J. Endocrinol., 2018, 179(2), 97-108. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1530/EJE-18-0138] [PMID: 29789410]
[124]
Webb, S.M.; Prieto, L.; Badia, X.; Albareda, M.; Catala, M.; Gaztambide, S.; Lucas, T.; Páramo, C.; Picó, A.; Lucas, A.; Halperin, I.; Obiols, G.; Astorga, R. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: Development and psychometric properties. Clin. Endocrinol. (Oxf.), 2002, 57(2), 251-258. [LoE ⊗⊗⊗Ο]
[http://dx.doi.org/10.1046/j.1365-2265.2002.01597.x]

Rights & Permissions Print Cite
Article Metrics
18
1
© 2024 Bentham Science Publishers | Privacy Policy